MedPath

Search of a new tumor marker and examination of usefulness by multi-institutinal study

Not Applicable
Recruiting
Conditions
Breast cancer, Thyroid cancer, Esophageal cancer, Gastric cancer, Colon cancer, Liver cancer, Biliary cancer, Pancreatic cancer
Registration Number
JPRN-UMIN000014530
Lead Sponsor
Toho Univerisity
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Patients who are judged inappropriate for this study by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Tumor markers to be analyzed are as follows. Positive rate of each tumor marker. Analysis of correlation with clinicopathological factors and various blood concentration. -New tumor markers(cancer-specific protein and IgG antibody cancer antigen-specific antibody such as SEREX) -Existing tumor markers(p53 antibody, CEA, SCC-Ag, CYFRA21-1, AFP, CA19-9, CA125, midkine, TPA, and IAP)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath